DUBLIN, June 1, 2022
/PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) today
announced that Ms. Alison Ives has
been promoted to Executive Vice President and Chief Scientific
Officer. In this role, Ms. Ives will be responsible for providing
global oversight and coordination of Perrigo's research and
development, regulatory and innovation efforts. She will join the
Company's Operating Committee and report to President and Chief
Executive Officer, Murray S.
Kessler.
Commenting on the appointment, Mr. Kessler stated, "We are
building the next leaders of Perrigo through both internal and
external talent. Perrigo's Scientific Office plays an incredibly
important role working with our businesses to propel innovation
across a wide range of regulatory categories and geographical
regions. After leading our Consumer Self-Care International
Regulatory Affairs and then our Consumer Self-Care Americas R&D
teams, Alison worked diligently to ensure the health of Perrigo's
product portfolio and helped establish a strategic framework that
will fuel future innovation. Her 20 years of regulatory and
R&D experience, along with her proven expertise in driving
product development and portfolio management will be essential for
accelerating our consumer self-care growth."
Ms. Ives said, "I am honoured to have been promoted to this
important role for Perrigo. In the past few years, under
Jim Dillard's leadership, we have
made enormous progress to strengthen the pipeline to more than
$500 million in potential revenue.
Together with the many talented people in our organization, I am
confident that we will deliver highly successful and much needed
innovation for customers and consumers."
Ms. Ives, who joined Perrigo through the acquisition of Omega
Pharma in 2015, previously worked for 11 years with AstraZeneca in
a variety of regional and global leadership roles within the
Scientific office, while sitting on New Product Development Teams
across five therapeutic areas. Early in her career, she worked as a
laboratory biochemist, researching drug discovery targets before
making the move into industry. In 2021, Ms. Ives received a
prestigious MBE award from the UK government for services to
healthcare, reflecting her lifelong passion to make lives
better.
About Perrigo
Perrigo Company plc (NYSE: PRGO) is a leading provider of
Consumer Self-Care Products and over-the-counter (OTC) health and
wellness solutions that enhance individual well-being by empowering
consumers to proactively prevent or treat conditions that can be
self-managed. Led by its consumer self-care strategy, Perrigo is
the largest store brand OTC player in the U.S. in the categories in
which it competes under customer 'own brand' labels and a top 10
OTC company by revenue in Europe.
Visit Perrigo online at www.perrigo.com.
Forward-Looking Statements
Certain statements in this press release are "forward-looking
statements." These statements relate to future events or the
Company's future financial performance and involve known and
unknown risks, uncertainties and other factors that may cause the
actual results, levels of activity, performance or achievements of
the Company or its industry to be materially different from those
expressed or implied by any forward-looking statements. In some
cases, forward-looking statements can be identified by terminology
such as "may," "will," "could," "would," "should," "expect,"
"forecast," "plan," "anticipate," "intend," "believe," "estimate,"
"predict," "potential" or the negative of those terms or other
comparable terminology. The Company has based these forward-looking
statements on its current expectations, assumptions, estimates and
projections. While the Company believes these expectations,
assumptions, estimates and projections are reasonable, such
forward-looking statements are only predictions and involve known
and unknown risks and uncertainties, many of which are beyond the
Company's control, including: the effect of the coronavirus
(COVID-19) pandemic and its variants and associated supply chain
impacts on the Company's business; general economic, credit, and
market conditions; the impact of the war in Ukraine and any escalation thereof, including
the effects of economic and political sanctions imposed by
the United States, United Kingdom, European Union, and other
countries related thereto; the outbreak or escalation of conflict
in other regions where we do business; future impairment charges;
customer acceptance of new products; competition from other
industry participants, some of whom have greater marketing
resources or larger market shares in certain product categories
than the Company does; pricing pressures from customers and
consumers; resolution of uncertain tax positions, including the
Company's appeal of the draft and final Notices of Proposed
Assessment ("NOPAs") issued by the U.S. Internal Revenue Service
and the impact that an adverse result in any such proceedings would
have on operating results, cash flows, and liquidity; pending and
potential third-party claims and litigation, including litigation
relating to the Company's restatement of previously-filed financial
information and litigation relating to uncertain tax positions,
including the NOPAs; potential impacts of ongoing or future
government investigations and regulatory initiatives; potential
costs and reputational impact of product recalls or sales halts;
the impact of tax reform legislation and/or changes in
healthcare policy; the timing, amount and cost of any share
repurchases; fluctuations in currency exchange rates and interest
rates; the Company's ability to achieve the benefits expected from
the sale of its Rx business and the risk that potential costs or
liabilities incurred or retained in connection with that
transaction may exceed the Company's estimates or adversely affect
the Company's business or operations; the Company's ability to
achieve the benefits expected from the acquisition of Héra SAS
("HRA Pharma") and the risks that the Company's synergy estimates
are inaccurate or that the Company faces higher than anticipated
integration or other costs in connection with the acquisition;
risks associated with the integration of HRA Pharma, including the
risk that growth rates are adversely affected by any delay in the
integration of sales and distribution networks;; the consummation
and success of other announced and unannounced acquisitions or
dispositions, and the Company's ability to realize the desired
benefits thereof; and the Company's ability to execute and achieve
the desired benefits of announced cost-reduction efforts and
strategic and other initiatives. An adverse result with respect to
the Company's appeal of any material outstanding tax assessments or
pending litigation, including securities or drug pricing matters,
could ultimately require the use of corporate assets to pay such
assessments, damages from third-party claims, and related interest
and/or penalties, and any such use of corporate assets would limit
the assets available for other corporate purposes. These and other
important factors, including those discussed under "Risk Factors"
in the Company's Form 10-K for the year ended December 31, 2021, as well as the Company's
subsequent filings with the United States Securities and Exchange
Commission, may cause actual results, performance or achievements
to differ materially from those expressed or implied by these
forward-looking statements. The forward-looking statements in this
press release are made only as of the date hereof, and unless
otherwise required by applicable securities laws, the Company
disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/perrigo-promotes-alison-ives-to-role-of-chief-scientific-officer-301558934.html
SOURCE Perrigo Company plc